<DOC>
	<DOCNO>NCT01791491</DOCNO>
	<brief_summary>The purpose study evaluate well adolescent kidney transplant patient tolerate single dose belatacept receive least 6 month transplant surgery , body handle drug .</brief_summary>
	<brief_title>Pharmacokinetics , Safety Tolerability Single-dose Belatacept Adolescent Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Abatacept</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Male Female subjects,1217 year old Receiving CNIbased maintenance immunosuppression since time renal transplantation accordance local standard care Stable renal function , opinion investigator , cGFR &gt; 45 mL/min/1.73m2 time enrollment ( per update Schwartz Formula ) Adolescent Recipients renal allograft live donor decease donor least 6 month prior enrollment Subject must receive calcineurin inhibitor ( CNI ) base [ cyclosporine ( CsA ) [ formulation ] Tacrolimus ( TAC ) ] immunosuppressive regimen Subject must receive adjunctive background maintenance immunosuppression mycophenolate mofetil ( MMF ) entericcoated mycophenolate sodium ( ECMPS ) /mycophenolic acid ( MPA ) Subjects may receive maintenance corticosteroid accordance local standard care Negative Interferon Gamma Release Assay ( IGRA ) QuantiFERONTB Gold test TSpotTB FOCBP must negative serum urine pregnancy test within 24 hrs prior start study medication Subject must stable estimate glomerular filtration rate ( GFR ) â‰¥45 mL/min/1.73m2 ( updated Schwartz formula ) EpsteinBarr virus ( EBV ) serostatus negative unknown time transplant screen History treat biopsy proven acute rejection ( BPAR ) within 3 month prior enrollment Subjects experience 1 episode acute rejection ( AR ) current allograft antibodymediated AR Significant proteinuria Active infection</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>